Pharmaceuticals—regulatory framework

Introduction to the regulation of medicinal products

A medicinal product is defined as a substance that is either:

  1. presented as preventing or treating disease, or

  2. used to correct or modify a physiological function by pharmacological, immunological or metabolic action, or to make a medical diagnosis

It is often obvious whether a product should be classified as a medicinal product, medical device, cosmetic product, food, or a biocide. On the other hand, the regulatory status of so-called ‘borderline products’ is not immediately clear. The regulatory classification of a product can have important ramifications, for example, on how the product is regulated (and by whom), how long it will take before such product can be commercialised (especially if pre-market approval is required), how the product can be marketed and what advertising claims can be made etc. For an analysis of the definition of medicinal product and the borderline between medicinal products and other products, see Practice Note: Introduction to borderline products.

The borderline between cosmetic products and those that are regulated as a medicinal product or medical device or have health claims

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

Life Sciences weekly highlights—12 March 2026

This week's edition of Life Sciences weekly highlights includes news that the EMA has published draft guidance from the Accelerating Clinical Trials in the EU (ACT EU) initiative on the conduct of clinical trials during public health emergencies, the MHRA has published and updated several key guidance documents ahead of amendments to the new UK clinical trials regulations and has announced the publication of a new analysis on the global impact of UK health data resource. Also included, is news that MedTech Europe has commented on the EU–US trade framework and the development on US tariff measures, and has also joined an industry statement calling for harmonised rules under the Circular Economy Act, the European Commission and Switzerland have signed a broad package of agreements to simplify trade in goods such as medical devices, Medicines for Europe has urged stronger supply security measures in Critical Medicines Act trilogues, the Commission has identified safety and labelling non-compliance in dermal fillers, the Association of the British Pharmaceutical Industry (ABPI) has outlined outcomes of the December 2025 VPAG review, the Department of Health and Social Care (DHSC) has completed its review of the genetic testing and insurance code, and the UK Space Agency, the MHRA, the Regulatory Innovation Office (RIO) and the Civil Aviation Authority (CAA) have announced a collaborative effort to develop a regulatory framework for in-orbit pharmaceutical manufacturing, among other stories.

View Life Sciences by content type :

Popular documents